"Human papillomavirus 16" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A type of ALPHAPAPILLOMAVIRUS especially associated with malignant tumors of the CERVIX and the RESPIRATORY MUCOSA.
| Descriptor ID |
D052162
|
| MeSH Number(s) |
B04.280.210.655.050.616 B04.613.204.655.050.616
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Human papillomavirus 16".
Below are MeSH descriptors whose meaning is more specific than "Human papillomavirus 16".
This graph shows the total number of publications written about "Human papillomavirus 16" by people in this website by year, and whether "Human papillomavirus 16" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 2 | 1 | 3 |
| 2007 | 0 | 3 | 3 |
| 2008 | 3 | 1 | 4 |
| 2009 | 4 | 0 | 4 |
| 2010 | 2 | 2 | 4 |
| 2011 | 5 | 3 | 8 |
| 2012 | 6 | 2 | 8 |
| 2013 | 5 | 5 | 10 |
| 2014 | 3 | 1 | 4 |
| 2015 | 6 | 6 | 12 |
| 2016 | 2 | 4 | 6 |
| 2017 | 5 | 4 | 9 |
| 2018 | 0 | 4 | 4 |
| 2019 | 3 | 2 | 5 |
| 2020 | 0 | 1 | 1 |
| 2021 | 0 | 1 | 1 |
| 2022 | 1 | 2 | 3 |
| 2023 | 0 | 7 | 7 |
| 2024 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Human papillomavirus 16" by people in Profiles.
-
Tsyn-Seq: a T-cell Synapse-Based Antigen Identification Platform. Cancer Immunol Res. 2024 May 02; 12(5):530-543.
-
Single-tube four-target lateral flow assay detects human papillomavirus types associated with majority of cervical cancers. Anal Biochem. 2024 May; 688:115480.
-
A novel tailed primer nucleic acid test for detection of HPV 16, 18 and 45 DNA at the point of care. Sci Rep. 2023 11 21; 13(1):20397.
-
Polymorphisms in the Nonhomologous End-joining DNA Repair Pathway are Associated with HPV Integration in Cervical Dysplasia. Cancer Prev Res (Phila). 2023 08 01; 16(8):461-469.
-
Phase II Trial of MEDI0457 and Durvalumab for Patients With Recurrent/Metastatic Human Papillomavirus-Associated Cancers. Oncologist. 2023 07 05; 28(7):618-623.
-
An integrated isothermal nucleic acid amplification test to detect HPV16 and HPV18 DNA in resource-limited settings. Sci Transl Med. 2023 06 21; 15(701):eabn4768.
-
Joint effect of human papillomavirus exposure, smoking and alcohol on risk of oral squamous cell carcinoma. BMC Cancer. 2023 May 19; 23(1):457.
-
Phase 1 study to determine the safety and dosing of autologous PBMCs modified to present HPV16 antigens (SQZ-PBMC-HPV) in HLA-A*02+ patients with HPV16+ solid tumors. Invest New Drugs. 2023 04; 41(2):284-295.
-
Safety and Efficacy of MEDI0457 plus Durvalumab in Patients with Human Papillomavirus-Associated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2023 02 01; 29(3):560-570.
-
Detection accuracy of the Cobas HPV assay for high-risk HPV in head and neck FNA biopsy specimens. Cancer Cytopathol. 2022 07; 130(7):523-530.